14 research outputs found
Ustekinumab as Induction and Maintenance Therapy for Crohnâs Disease
BACKGROUND
Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and inter-leukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohnâs disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.
METHODS
We randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials. The UNITI-1 trial included 741 patients who met the criteria for primary or secondary nonresponse to tumor necrosis factor (TNF) antagonists or had unacceptable side effects. The UNITI-2 trial included 628 patients in whom conventional therapy failed or unacceptable side effects occurred. Patients who completed
these induction trials then participated in IM-UNITI, in which the 397 patients who had a response to ustekinumab were randomly assigned to receive subcutaneous maintenance injections of 90 mg of ustekinumab (either every 8 weeks or every 12 weeks) or placebo. The primary end point for the induction trials was a clinical response at week 6 (defined as a decrease from baseline in the Crohnâs Disease Activity Index [CDAI] score of â„100 points or a CDAI score <150). The primary end point for the maintenance trial was remission at week 44 (CDAI score <150).
RESULTS
The rates of response at week 6 among patients receiving intravenous ustekinumab at a dose of either 130 mg or approximately 6 mg per kilogram were significantly higher
than the rates among patients receiving placebo (in UNITI-1, 34.3%, 33.7%, and 21.5%, respectively, with Pâ€0.003 for both comparisons with placebo; in UNITI-2, 51.7%, 55.5%, and 28.7%, respectively, with P<0.001 for both doses). In the groups receiving maintenance doses of ustekinumab every 8 weeks or every 12 weeks, 53.1% and 48.8%, respectively, were in remission at week 44, as compared with 35.9% of those receiving placebo (P = 0.005 and P = 0.04, respectively). Within each trial, adverse-event rates were similar among treatment groups.
CONCLUSIONS
Among patients with moderately to severely active Crohnâs disease, those receiving intravenous ustekinumab had a significantly higher rate of response than did those receiving placebo. Subcutaneous ustekinumab maintained remission in patients who had a clinical response to induction therapy. (Funded by Janssen Research and Development; ClinicalTrials.gov numbers, NCT01369329, NCT01369342, and NCT01369355.
Memristor devices for neural networks
Neural network technologies have taken center stage owing to their powerful computing capability for supporting deep learning in artificial intelligence. However, conventional synaptic devices such as SRAM and DRAM are not satisfactory solutions for neural networks. Recently, several types of memristor devices have become popular alternatives because of their outstanding characteristics such as scalability, high performance, and non-volatility. To understand the characteristics of memristors, a comparison among memristors has been made, considering both maturity and performance. Magneto-resistance random access memory, phase-change random access memory, and resistive random access memory among the proposed memristors are good candidates as synaptic devices for weight storage and matrixvector multiplication required in artificial neural networks (ANNs). Moreover, these devices play key roles as synaptic devices in research for bio-plausible spiking neural networks (SNNs) because their distinctive switching properties are well matched for emulating synaptic and neuron functions of biological neural networks. In this paper we review motivation, advantage, technology, and applications of memristor devices for neural networks from practical approaches of ANNs to futuristic research of SNNs, considering the current status of memristor technology